# caohaotian: Phase 3 study in Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma (300 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | caohaotian |
| Sponsor type | Academic and hospital |
| Study | Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma |
| NCT ID | NCT07827872 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Oral Squamous Cell Carcinoma (OSCC); Head and Neck Squamous Cell Carcinoma; Early-stage Oral Cancer |
| Intervention types | drug, procedure |
| Target enrollment | 300 |
| Site countries | China |
| Posted | 2026-09-18 |
| Planned start | 2026-10-01 |
| Event | Newly registered study |
| Event date | 2026-09-18 |

## Why this score
- Phase 3: multi-site, larger budget.
- 300 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07827872). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.